reports
ORYZON Strengthens Vafidemstat Patent Portfolio With U.S. Notice of Al...
ORYZON Strengthens Vafidemstat Patent Portfolio With U.S. Notice of Allowance Covers the use of vafidemstat for treating non-aggressive symptoms of Borderline Personality Disorder (BPD) MADRID, and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application US 17/439,575, entitled “Methods of treating borderline personality disorder”...
ORYZON Announces U.S. Patent Grant Covering Iadademstat Combinations w...
ORYZON Announces U.S. Patent Grant Covering Iadademstat Combinations with Venetoclax Key combination for the treatment of first-line AMLRecent data from an ongoing study in first-line AML showed a 100% overall response rate (ORR) with iadademstat in combination with venetoclax and azacitidine MADRID and CAMBRIDGE, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. patent US12,...
ORYZON Expands Patent Protection for Iadademstat with Grant Decision i...
ORYZON Expands Patent Protection for Iadademstat with Grant Decision in Mexico Covering Combinations with PD-1/PD-L1 Inhibitors Key combination for the treatment of Small Cell Lung Cancer MADRID and CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the Mexican Patent Office has issued a decision to grant for its patent application MX/a/2021/011610, entitled “Combinations of iadademstat for cancer therapy”. The allowed claims protect t...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON Reports Financial Results and Corporate Update for Quarter Ende...
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025 Strong cash position at year-end 2025: $33.3 million (€28.4 million) CNS(Vafidemstat) Appointed renowned Rolando Gutierrez-Esteinou, M.D. as new CMO for CNSPreparing protocol resubmission to incorporate FDA guidance on Phase III PORTICO-2 trial in aggression in BPDOngoing expansion of Phase IIb schizophrenia trial into additional EU countriesFinalizing preparations for new Phase II trial in aggression in autism spectrum disorder as a part of the IPCEI EU Grant in personalized medicine Oncology – Hema...
ORYZON Receives European Medicines Agency Approval to Initiate a Phase...
ORYZON Receives European Medicines Agency Approval to Initiate a Phase II Study of iadademstat in Essential Thrombocythemia MADRID and CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that the European Medicines Agency (EMA) has authorized its Clinical Trial Application (CTA) to initiate a Phase II study of iadademstat, Oryzon’s potent and selective LSD1 inhibitor currently in clinical development in oncology and hematology, for th...
ORYZON to Participate in Upcoming Events in February and March
ORYZON to Participate in Upcoming Events in February and March MADRID and CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events: Bio-Neuroscience 2026, February 24-27Location: Hotel Jakarta, Amsterdam SmallCap Event 20th Edition, March 17Location: Les Salons Hoche, Paris BIO-Europe Spring 2026, March 23-25Location: Feira Internacional de Lisboa (FIL), Lisbon LSX World Congr...
ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as C...
ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS Based in New Jersey (USA), to lead ORYZON’s CNS clinical development MADRID and CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer, CNS Programs. Dr. Gutierrez-Esteinou is a Harvard-trained psychiatrist and an accomplished global clinical development executive with mor...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON Announces First Patient Dosed in an Investigator-Initiated Phas...
ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in Extensive Stage Small Cell Lung Cancer Exploring the combination with atezolizumab and radiation therapyStudy led by Yale University MADRID, Spain and CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, announced today that the first patient has been dosed in an investigator-initiated Phase Ib dose-finding trial evaluating iadademstat, Oryzon’s potent and sele...
ORYZON Strengthens Patent Portfolio for Vafidemstat With New Decision ...
ORYZON Strengthens Patent Portfolio for Vafidemstat With New Decision to Grant in Japan For the treatment of aggression and social withdrawal MADRID and CAMBRIDGE, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that it has received a “Decision to grant” communication from the Japanese Patent Office for its patent application JP2023-136283, titled “Methods of treating behavior alterations”, related to vafidemstat, Oryzon’s LSD1 inhibitor in clinica...
ORYZON to Participate in Upcoming Events in January
ORYZON to Participate in Upcoming Events in January MADRID and CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events: 9th Sachs Annual Neuroscience Innovation Forum, January 11Location: Marines’ Memorial Club, San Francisco, USAPresentation type: Company presentationPresentation time: 10:35 am (PST) 44th Annual J.P. Morgan Healthcare Conference, January 12-15Location: San Fra...
ORYZON Expands Global Patent Protection for Iadademstat with Grant Dec...
ORYZON Expands Global Patent Protection for Iadademstat with Grant Decision in Japan Covering Combinations with PD-1/PD-L1 Inhibitors Key combination for the treatment of Small Cell Lung Cancer MADRID and CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the Japanese Patent Office has issued a Decision to Grant for its patent application JP2021-557187, entitled “Combinations of iadademstat for cancer therapy”. Following formal grant, ...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON Announces the Voting Results of December 2025 Extraordinary Gen...
ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting 37.8% of voting rights present or representedAll resolutions were approved MADRID and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the results of voting at the Extraordinary General Shareholders' Meeting held last Friday in Madrid. A total of 33,581,589 of the Company's issued and outstanding voting rights (representing 37.7938% of the share ...
ORYZON Presents Data for Iadademstat Combinations in AML at the Americ...
ORYZON Presents Data for Iadademstat Combinations in AML at the American Society of Hematology (ASH) 67th Annual Meeting 100% Overall response rate (ORR) in triple combo study with azacitidine and venetoclax in newly diagnosed AML patients80% CR and 90% Composite Complete Remissions (CCR); median OS not reached after 9 months and good tolerability70% of patients derived to Hematopoietic Stem Cell Transplantation (HSCT) 67% CCR at the expansion dose in study evaluating iadademstat plus gilterinib in FLT3-mutated relapsed/refractory AML patients; 47% CR+CRhTreatment was safe and well tolerate...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.